Testing oxygen-deprived red blood cells in sickle cell anemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a special way of preparing red blood cells for transfusion to see if it can help people with sickle cell anemia. If you already get regular transfusions, this study might offer a new option that could reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 7 years or older.
- You must have a diagnosis of sickle cell anemia (specifically HbSS or HbS beta-zero thalassemia).
- You must be on a regular blood transfusion program for at least 6 months, with transfusions at least 14 days apart on average.
- If you take iron chelation therapy (to remove extra iron), your dose must have been stable for at least 3 months.
- You must not be pregnant or planning pregnancy within the next 14 months.
- You must not have other sickle cell variants like HbSC or HbS beta-plus thalassemia, or be currently evaluated for gene therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy that may help people with severe sickle cell disease by editing their own blood stem cells to produce healthy red blood cells. It aims to reduce painful crises and other complications.
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This trial tests a specific type of bone marrow transplant for people with sickle cell disease (or certain other blood disorders) who have had serious complications despite standard care. It aims to see if removing the patient’s immune cells and using a matched donor’s cells can improve outcomes and reduce complications.
Hear when a new Sickle Cell Anemia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.